GlassScriptPhysician profile
David Maldonado
NPI 1386624476
$1,727.11
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $47.20 · 2021: $31.48 · 2022: $19.19 · 2023: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $902.18 | 2019 | |
| Stryker Corporation | $192.51 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $78.75 | 2019 | |
| Genentech USA, INC. | $66.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.16 | 2019 | |
| Sunovion Pharmaceuticals INC. | $58.28 | 2019 | |
| Masimo Corporation | $47.20 | 2020 | |
| Jazz Pharmaceuticals INC. | $41.05 | 2019 | |
| Medtronic, INC. | $39.36 | 2023 | Biosyn |
| Gilead Sciences, INC. | $36.28 | 2019 | |
| Advanced Respiratory, INC | $32.32 | 2019 | |
| Electromed, INC. | $31.48 | 2021 | |
| Mylan Specialty L.P. | $29.08 | 2019 | |
| Glaxosmithkline, LLC. | $27.94 | 2019 | |
| United Therapeutics Corporation | $19.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.74 | 2019 | |
| Livanova USA, INC. | $14.00 | 2019 | |
| Lilly USA, LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.